Abbott confirmed that its $23 billion acquisition of Exact Sciences has cleared regulatory hurdles and is set to close, bringing Cologuard, Oncotype DX and other cancer‑screening and diagnostic platforms into Abbott’s diagnostics franchise. Abbott expects the deal to add roughly $3 billion of incremental sales in 2026 and strengthen its presence in oncology diagnostics. Chairman and CEO Robert Ford said the transaction advances Abbott’s strategy to expand care access and diagnostic leadership.